Literature DB >> 31811803

A case report of generalized tetanus in a 42-year-old man with dental infection.

Maria Ulfa1, Nuril Auliya Husna2.   

Abstract

Background In the post-vaccination era, as it is today, generalized tetanus is a rare diagnosis, although mortality and morbidity continue to increase significantly throughout the world. Infection occurs when the Clostridium tetani spores are introduced into wounds, skin lesions and infections. The symptoms often begin with stiffness or spasms in the jaw muscles; they are called trismus or "lockjaw" and/or then spread to the neck and abdominal muscles. Case presentation This is a report of a 42-year-old man who was referred to the hospital with dysphagia, rigidity and trismus. He was diagnosed with generalized tetanus with a Philips score of 15. The patient was admitted to the isolation unit, received treatment that included procaine penicillin, metronidazole, diazepam, human tetanus immunoglobulin (TIG) and anti-tetanus serum (ATS). Treatment was considered according to the guidelines of the World Health Organization, and also, the drug dose has no adverse event reaction during the treatment. Conclusion The therapeutic response is related to the identification and appropriate treatment, especially in hospitalized patients with inadequate immunization so that patients recover soon.

Entities:  

Keywords:  dental infection; generalized tetanus; trismus

Mesh:

Year:  2019        PMID: 31811803     DOI: 10.1515/jbcpp-2019-0243

Source DB:  PubMed          Journal:  J Basic Clin Physiol Pharmacol        ISSN: 0792-6855


  2 in total

1.  Unusual generalized tetanus evolving from odontogenic infection: A case report and review of recent literature.

Authors:  Muhammad Akbar; Muhammad Ruslin; Andi Sitti Hajrah Yusuf; Paolo Boffano; Kei Tomihara; Tymour Forouzanfar
Journal:  Heliyon       Date:  2022-09-28

2.  Severe tetanus following ulcerated skin cancer: Case report.

Authors:  Jin Wang; Ying Yang; Chao Yang; Wen Lv; Shihai Xu; Fei Shi; Aijun Shan
Journal:  Medicine (Baltimore)       Date:  2020-07-31       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.